Premium
CD44/CD24 expression on salivary glands malignant neoplasms (SGMN)
Author(s) -
Soave Danilo Figueiredo,
Costa João Paulo Oliveira,
Silveira Giorgia Gobbi,
Ianez Renata Carolina Fraga,
Oliveira Lucinei Roberto,
Lourenço Silvia Vanessa,
Silva Alfredo Ribeiro
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.lb456
Subject(s) - cd24 , cd44 , lymph node , medicine , immunohistochemistry , stage (stratigraphy) , pathology , oncology , cancer research , cancer , biology , cell , cancer stem cell , genetics , paleontology
Background CD44 is the binding site for hyaluronic acid, and CD24 is a receptor that interacts with P‐selectin to induce tumor progression. Present study aims to evaluate CD44/CD24 expression on SGMNs and correlated these data with clinicopathologic features. Methods Immunohistochemical stains for CD44/CD24 were performed on 69 SGMN samples. CD44/CD24 expression was correlated to patient clinicopathologic features and outcome. Results CD44 expression was associated with the primary site of neoplasm (p=0.046). CD24 was associated with clinical stage III/IV (p=0.008), T stage (p=0,27) and lymph node (p=0,001). The CD44/CD24 profiles were associated with the primary site of injury (p=0.005), lymph node (p=0.011) and T stage (p=0.023). Conclusion in summary, we have presented some evidence that the analysis of CD44/CD24 expression could give prognostic information associated to clinicopathologic features in SGMN.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom